Heating Things Up…While Keeping Our Cool!
Heating Things Up…While Keeping Our Cool!
 Heating Things Up…While Keeping Our Cool!
STM Newsletter
August 2021
Congratulations to the winners of the 2021 STM Awards!

The Society for Thermal Medicine is pleased to announce the winners of the prestigious 2021 STM Awards.
Please join us in congratulating them and join us at ICHO 2021 for their award presentations!

2021 J. Eugene Robinson Award Winner (Biology):
Dr. Michael Horsman
B.Sc.(Hons), PhD, D.M.Sc.

2021 George M. Hahn Award Winner:
Dr. Rolf D. Issels
Prof. Dr. med. Dipl. Biochem.

2021 Tsudomu Sugahara Award Winner:
Dr. Mark Dewhirst

All active members! Reminder to Vote!
2021 STM Officer and Council Election
The 2021 STM Election is underway and all active members were sent a link to the online ballot on August 17, 2021.
If you have not yet voted, please do so by the deadline of September 17, 2021.
If you are an active member and did not receive your ballot, please check your spam/junk folder and contact stm@allenpress.com if you have any questions. 
Thank you for participating in this important society business!
Virtual Symposia and Upcoming Events
October 6-9, 2021: The 13th International Congress of Hyperthermic Oncology will be virtual this fall.
ICHO occurs every four years and combines expertise from three partnering societies:  the Asian Society of Hyperthermic Oncology (ASHO), the Society for Thermal Medicine (STM), and the European Society for Hyperthermic Oncology (ESHO).
Check out the scientific program which is now online and learn more about this year's sessions. A vast selection of topics related to Hyperthermic Oncology will be addressed in plenary lectures, scientific sessions, courses, industry sponsored symposia and many more educational formats.
Hyperthermia Therapy Practice School, Oct. 29-30, 2021

Save the date! Hyperthermia Therapy Practice School - October 29-30, 2021

After a successful first edition, the University of Maryland School of Medicine has the pleasure to announce the second edition of the Hyperthermia Therapy Practice School. This 2-day CME-accredited course will provide attendees with theoretical and practical aspects of superficial, interstitial, and deep hyperthermia therapy (HT). The first day will include lectures and the review of clinical cases to explain the different approaches to treat different treatment sites. On the second day, small groups will facilitate in-depth training of practical guidelines for HT treatment delivery, with hands-on practice with HT software and hardware using anatomical experimental phantoms. Attending practitioners will be made aware of the powerful adjuvant effect of combining HT with the different forms of radiation treatment and will benefit from a HT formal training in a clinical environment.
  • Dates: October 29-30, 2021
  • Location: Baltimore Maryland, USA
  • CME credits: Maximum of 15.50 AMA PRA Category 1 Credits™
  • Course Directors: Zeljko Vujaskovic, MD, PhD and Dario Rodrigues, PhD
  • Target audience: Oncologists, Medical Physicists, Radiation Therapists, Nurses, Students, Industry
More information and registration HERE.
Membership - Support STM during this critical time
Get geared up for ICHO by renewing your STM membership!  Now is a critical time to show your support for STM and rebuild your connections.
Renew your membership here for 2021: https://www.thermaltherapy.org/ebusSFTM/MEMBERSHIP.aspx
Membership in The Society for Thermal Medicine is open to anyone interested in the study of thermal medicine.
Membership rights and privileges include:
  • Participating in society elections
  • Committee service
  • Access to restricted “members-only” areas of the STM website
  • Discount on ICHO 2021 registration fees
  • Free registration to all STM webinars/mini-symposia
  • A 30% discount on IJH article submission fees
  • Complementary sponsorship of 2 junior investigators 
Connect with us!
If you have suggestions for how we can better improve STM as we delve together into these new plans, please reach out, and let us know:
International Journal of Hyperthermia updates
Do you like learning more about Thermal Medicine? Remember that STM is the official sponsor for the International Journal of Hyperthermia.

STM members receive a valuable 30% discount on publishing charges.  Now is a great time to work from home and write your manuscripts for submission to IJH!  IJH is on track to receive a record number of submissions this year and its impact factor continues to increase annually (3.914 for 2021).  
IJH is always interested in innovative ideas to increase the breadth of the journal and we strongly hope that the special issues venue will help in the expansion. We are open to additional Industry-Sponsored or Foundation sponsored Special Issues. Please let us know if you have an idea for one!
Journal Update from the Editor:
The International Journal of Hyperthermia recently held a board meeting, with over 30 section editors from across the globe in attendance.  One of our goals will be to select publications that will make a higher impact in the field, which will in turn result in a higher rejection rate.  In order to advance the prestige of IJH we are working to adopt new procedures for enhanced screening during author submission.  Updated policy announcements will be issued soon.
IJH Special Issue on Focused Ultrasound

IJH is pleased to announce that the Special Issue on Focused Ultrasound, edited by Professor Lian Zhang, has been released.
Please click the link HERE to access the issue.

Featured International Journal of Hyperthermia highlighted articles
Muhammad Zubair, Matthew S. Adams & Chris J. Diederich
Published online: 11 August 2021 
To investigate the design of an endoluminal deployable ultrasound applicator for delivering volumetric hyperthermia to deep tissue sites as a possible adjunct to radiation and chemotherapy.
This study considers an ultrasound applicator consisting of two tubular transducers situated at the end of a catheter assembly, encased within a distensible conical shaped balloon-based reflector that redirects acoustic energy distally into the tissue. The applicator assembly can be inserted endoluminally or laparoscopically in a compact form and expanded after delivery to the target site. Comprehensive acoustic and biothermal simulations and parametric studies were employed in generalized 3D and patient-specific pancreatic head and body tumor models to characterize the acoustic performance and evaluate heating capabilities of the applicator by investigating the device at a range of operating frequencies, tissue acoustic and thermal properties, transducer configurations, power modulation, applicator positioning, and by analyzing the resultant 40, 41, and 43 °C isothermal volumes and penetration depth of the heating volume. Intensity distributions and volumetric temperature contours were calculated to define moderate hyperthermia boundaries.
Parametric studies demonstrated the frequency selection to control volume and depth of therapeutic heating from 62 to 22 cm3 and 4 to 2.6 cm as frequency ranges from 1 MHz to 4.7 MHz, respectively. Width of the heating profile tracks closely with the aperture. Water cooling within the reflector balloon was effective in controlling temperature to 37 °C maximum within the luminal wall. Patient-specific studies indicated that applicators with extended OD in the range of 3.6–6.2 cm with 0.5–1 cm long and 1 cm OD transducers can heat volumes of 1.1–7 cm3, 3–26 cm3, and 3.3–37.4 cm3 of pancreatic body and head tumors above 43, 41, and 40 °C, respectively.
In silico studies demonstrated the feasibility of combining endoluminal ultrasound with an integrated expandable balloon reflector for delivering volumetric hyperthermia in regions adjacent to body lumens and cavities.
Zhimei Huang, Zhixing Guo, Jiayan Ni, Mengxuan Zuo, Tianqi Zhang, Rong Ma, Chao An & Jinhua Huang
Published online: 10 August 2021 
To evaluate the incidence, risk factors and clinical significance of four types of tumor progression (TP) after microwave ablation (MWA) of single hepatocellular carcinoma (HCC) of <5 cm.
The data of 340 treatment-naïve, HCC patients with a single HCC of <5 cm underwent MWA between April 2012 and November 2017 were retrospectively reviewed. TPs including local tumor progression (LTP), intrahepatic distant recurrence (IDR), aggressive intrasegmental recurrence (AIR) and extrahepatic distant recurrence (EDR) were reviewed and compared between BCLC stage 0 and A. Univariate and multivariate analysis were performed on clinicopathological variables and different TPs to identify factors affecting long-term overall survival (OS).
In a median follow-up period of 25.6 months (range, 3.1–61.4 months), the rate of LTP, IDR, AIR and EDR was 6.2% (21/340), 29.1% (98/340), 3.2% (11/340) and 7.9% (27/340). The four types of TP occurrence rates in BCLC stage 0 were comparable to those in BCLC stage A (p = 0.492, 0.971, 0.681 and 0.219). Univariate analysis showed that age (p < 0.001, hazard ratio [HR] = 2.783), comorbidities (p = 0.042, HR = 1.864), IDR, AIR and EDR (p = 0.027, HR = 1.719; p = 0.001, HR = 3.628; p = 0.009, HR = 2.638) were independently associated with OS. Multivariate analysis showed older age (p < 0.001, HR = 2.478), the occurrence of AIR (p < 0.001, HR = 2.648) and the occurrence of EDR (p = 0.002, HR = 2.222), were associated with poor OS.
The occurrence rate of IDR is the highest of all TPs following MWA of a single HCC of <5cm. Old age, AIR and EDR had an adverse effect on long-term OS.
Chao-Chih Wu, Yun-Ting Hsu, Chih-Long Chang
Published online: 1 July 2021
We aimed to determine the effects and possible mechanisms of hyperthermic intraperitoneal chemotherapy (HIPEC) in targeting ovarian cancer stem-like cells (CSCs).
Murine ovarian cancer cell lines presenting CSC surface markers were grown intraperitoneally in both immunocompetent and immunodeficient mice, which were then treated by intraperitoneal hyperthermia with the chemotherapeutic agents: paclitaxel and cisplatin. Tumor growth was measured by non-invasive luminescent imaging. Intraperitoneal immune cells, such as CD4+, CD8+ T cells, macrophages, and dendritic cells, were evaluated through flow cytometry analysis.
Combined hyperthermia and chemotherapy exhibited an efficient therapeutic effect in the immunocompetent mice. However, a similar effect was not observed in the immunodeficient mice. Intraperitoneal hyperthermia increased the number of Intraperitoneal macrophages and dendritic cells that were lost due to chemotherapy. Compared with ovarian cancer bulk cells, CSCs were more susceptible to phagocytosis by macrophages.
We demonstrated that the superior therapeutic efficacy and reduced proportion of CSCs associated with intraperitoneal hyperthermic chemotherapy were immune-related. Hyperthermia recruits the phagocytes that target surviving CSCs after chemotherapy. These results provide a novel mechanism for the efficacy of HIPEC in treating ovarian cancer.
Twitter Facebook Instagram LinkedIn
STM Business Office | PO Box 7065 | Lawrence, KS 66044-1897 USA
powered by emma